Cargando...
Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities
Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have been shown to have unprecedented efficacy in B cell malignancies, most notably in B cell acute lymphoblastic leukemia (B-ALL) with up to a 90% complete remission rate using anti-CD19 CAR-T cells. However, CAR T-cell therapy for so...
Gardado en:
| Publicado en: | Oncotarget |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5685771/ https://ncbi.nlm.nih.gov/pubmed/29163850 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19361 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|